The cost of treating relapsed indolent non-Hodgkin&apos;s lymphoma in an international setting: retrospective analysis of resource use by Herold, M et al.
haematologica vol. 87(7):july 2002
Correspondence: Klaus Hieke, NEOS Health Ltd., Parkstrasse 28,
CH-4102 Binningen, Switzerland. Phone: international
+41.61.4237030. Fax: international +41.61.4237043.
E-mail: klaus.hieke@neoshealth.com
The cost of treating relapsed indolent
non-Hodgkin’s lymphoma in an
international setting: retrospective
analysis of resource use
MICHAEL HEROLD,* STEFANO SACCHI,° KLAUS HIEKE#
*HELIOS-Klinikum Erfurt; II Medizinische Klinik, Abt.
Hämatologie/Onkologie, Erfurt, Germany; °Dip. di Scienze
Mediche, Radiologiche e Oncologiche, Università di Modena,
Italy; #NEOS Health Ltd, Binningen, Switzerland
Malignant Lymphomas 
research paper
haematologica 2002; 87:719-729
http://www.haematologica.ws/2002_07/719.htm
In the past 30 years there has been a steep risein the incidence of non-Hodgkin’s lymphoma(NHL) in the West, with incidences increasing by
approximately 3-4% annually since the early
1970s.1-3 Incidence rates in Germany and Italy
(1997) were approximately 14 per 100,000 popu-
lation.4 Higher incidence rates of approximately
20 per 100,000 population per year have been
reported in North America.5,6
Indolent B-cell lymphomas account for between
30–40% of these cases.7,8 Patients with indolent
disease typically show a median survival of
between 6–10 years from diagnosis, with treat-
ment characterized by serial remissions, gradual-
ly decreasing in duration regardless of the thera-
py employed. First-line therapy usually involves an
alkylating agent-based regimen and median
response durations of 12–30 months can be
achieved.9
Once relapse occurs patients are offered addi-
tional chemotherapy; however, there is currently
no single dominant treatment standard for
relapsed indolent NHL. Patients characteristically
undergo multiple cycles of therapy and a variety of
different regimens are in common use. Some are
internationally recognized, such as CHOP
(cyclophosphamide, doxorubicin, vincristine, pred-
nisone), while others are nationally specific, such
as DHAP (dexamethasone, high-dose cytarabine,
cisplatin), which is used in the treatment of
aggressive NHL, but also to treat relapsed indolent
NHL in France.
Recently the purine analog, fludarabine, has
shown comparatively good results.10 Studies using
fludarabine reported overall response rates rang-
ing from 30–99%, and event-free survivals of up
to 31 months.11–23 Fludarabine treatment was,
however, associated with adverse events, most
commonly neutropenia (40–62%), infections
and/or febrile episodes (15–19%) and deaths due
to infection (5-12%).14, 16, 24
Innovative new treatment options have been
scarce until the introduction of rituximab (mono-
Background and Objectives. Few economic data exist on
the treatment of indolent non-Hodgkin’s lymphoma (NHL)
and there are none in the published literature concern-
ing relapsed disease. This international analysis (Cana-
da, Germany, Italy) was established to estimate the over-
all direct cost of treating patients with relapsed indolent
NHL and determine the main cost components of treat-
ment. 
Design and Methods. Telephone interviews were used to
identify the most commonly used treatment regimens in
each country. CHOP, CVP and fludarabine were chosen
for economic analysis, which was based on retrospective
data from 424 patients.
Results. Overall treatment costs for a course of six cycles
varied more than 5-fold, from €3,445 to 17,940
between regimens and countries. The treatment setting
had a major impact on costs, with in-patient costs being
up to three times greater than the equivalent out-patient
values. Drug administration costs comprised 46–60% of
the overall treatment costs in the in-patient setting.
Adverse event management was the major cost compo-
nent for out-patient CHOP and CVP therapy (52–75%),
and a significant proportion (24–40%) of in-patient costs
for these regimens. Drug acquisition accounted for less
than half of treatment costs for most of the regimens
analyzed.
Interpretation and Conclusions. This study shows that
not simply drug acquisition costs, but the costs of drug
administration, particularly in the in-patient setting, and
adverse event management are major contributors to the
overall treatment costs for relapsed indolent NHL.
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clonal antibody-based therapy), which shows com-
parable efficacy to existing chemotherapy regi-
mens in mono-and combination therapy (ORR 46-
100%, progression-free survival up to 65.1+
months in combination with CHOP), but with bet-
ter tolerability.25–36
In addition to clinical effectiveness, the patien-
t’s quality of life and economic factors are impor-
tant in treatment choice. Adverse events such as
anemia, neutropenia, thrombocytopenia, nausea
and vomiting are commonly seen with many cyto-
toxic regimens. To date, limited published data are
available on the extent of adverse events during
treatment of relapsed indolent NHL, or their con-
tribution to the overall cost of treatment.
Extensive literature searches by ourselves and
others37 revealed very few published economic
analyses of direct or indirect costs of treating lym-
phoma, despite the call for more such evaluations
of all aspects of oncology management.38 A UK
analysis comparing resource utilization and treat-
ment costs of different schedules (CHOP vs. flu-
darabine vs. rituximab) for relapsed indolent NHL
has been published.39
The few other existing studies have examined the
costs of two comparatively new techniques – autol-
ogous bone marrow transplantation (ABMT)40-42 and
granulocyte colony-stimulating factor (G-CSF)
use43–45 in aggressive lymphoma. Only one study in
the Netherlands46 compared the cost of ABMT with
CHOP chemotherapy. In an improvement to this sit-
uation, Tolley et al. (British Office of Health Eco-
nomics) published an estimate of treatment costs
using published data and expert opinion.37
To our knowledge this is the first international
effort to study economic aspects of indolent NHL
management. Drawbacks to this evaluation includ-
ed: lack of pertinent published data, no standard
treatment for relapsed disease, there being a vari-
ety of treatment regimens in current use, and lim-
ited information on treatment patterns, adverse
events and resource use. 
This study was designed as a cost of illness study
to describe, rather than compare, treatment pat-
terns and their economic consequences in select-
ed Western countries from the third party payer-
perspective. Indirect costs (lost productivity) were,
therefore, not included in the analysis. The first
objective was to identify standard treatment prac-
tices in the countries reviewed, then collect retro-
spective data from the patients’ records. As this
study was designed as a cost of illness study it was
not appropriate to evaluate efficacy or remission
duration, as data were taken from one single cycle
of chemotherapy, and patients presented in differ-
ent cycles (typically 28 days) of treatment.
Design and Methods
Data collection
Data collection was a two-stage process:
1. Identification of treatment regimens. Explorato-
ry telephone interviews with pre-selected lym-
phoma specialists in Canada, Germany and Italy
were first conducted to determine the most
commonly used regimens for treatment of
relapsed indolent NHL. Interviews were per-
formed by an independent market research com-
pany (ISIS Research, UK) using native language
speakers and a set questionnaire. To be eligible
for inclusion, specialists interviewed had to
either run a hospital lymphoma clinic or be spe-
cialized in lymphoma management, treating 10
or more patients with relapsed indolent NHL per
year. Eligible specialists were then asked to list
their three most common protocols and the per-
centages of patients on each protocol. Eligible
data from 91 telephone interviews (April 1997)
were provided by 30 specialists each in Germany
and Italy, and 31 in Canada. The mean number
of patients seen by each specialist in the past
year ranged from 21 (Italy) to 39 (Germany).
2. Review of the patients’ records. A retrospective
case record form (CRF) was specifically designed
to obtain relevant treatment data from the
patients’ records. CRFs were mailed to each spe-
cialist who agreed to participate. Around 30% of
specialists who participated in the first stage
agreed to participate in the second stage as well,
with the remainder recruited specifically for the
second stage. A target of 50 patients per treat-
ment group and country was set (Table 2). In
total, CRFs were mailed to 179 specialists (91 in
Canada, 37 in Germany, 51 in Italy). For inclusion,
specialists had to see at least 10 patients with
relapsed indolent NHL per year, and treat 8 or
more patients with at least one of the selected
regimens. Specialists completed the CRFs by
extracting data from records of patients treated
for relapsed indolent NHL since 1990, and who
received one of the selected regimens. The mail-
ing and receipt of CRFs was handled by ISIS
Research to maintain confidentiality.
Four hundred and twenty-four completed CRFs
were returned from 89 eligible specialists (50 in
Canada, 19 in Germany, 20 in Italy, response rate
50%). The average number of CRFs completed per
specialist was 8.0 (Italy), 5.6 (Germany), and 3.5
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(Canada). In total, information was provided for 424
patients. Questions in the CRF referred to events
occurring during a single cycle of chemotherapy and
included six sections: the patient’s demographics;
treatment regimen; chemotherapy setting (i.e. in-
patient/out-patient); routine tests; treatment out-
come; and adverse event management (including
hospitalization and diagnostic tests). In-patients
were defined as patients who had at least one
overnight hospital stay for drug administration. 
Adverse events and any subsequent treatments
for events were recorded in five categories: nau-
sea/vomiting; neutropenia and fever/infections;
thrombocytopenia; anemia; and other. The use of
prophylactic treatment, occurrence of an adverse
event, any treatment, diagnostic test, out-patient
visit and days of hospitalization were recorded.
Cost calculations
Overall costs for each selected regimen were cal-
culated from the perspective of a third-party pay-
er as recommended by Garattini et al.47 National-
ly, the unit costs for each treatment, test or proce-
dure were used to calculate the cost per patient of
a single cycle of chemotherapy. Unit costs were
obtained from different sources, including pub-
lished price lists, national and regional sources, and
previously published economic studies. The unit
costs for medications may be an overestimate as
they are based on published price lists minus
wholesaler and retail pharmacy add-ons and will
not have reflected discounts which may have been
negotiated between the manufacturer and indi-
vidual hospitals. In counterbalance, figures used in
the out-patient setting may be underestimated,
particularly for Germany, because add-ons plus
pharmacy charges for drug preparation have not
been included. For Italy a 50% reduction on the
public price for drugs was considered for in-
patients. Each cycle was assumed to be represen-
tative of the cycles making up the whole course of
treatment for each patient. Results were expressed
as an average treatment cost per patient for a com-
plete course (six cycles) of chemotherapy.
The average costs per patient were presented for
both in-patient and out-patient treatment. Further
cost breakdowns of drug acquisition for the regi-
men, treatment administration, and treatment and
management of adverse events allowed the main
cost component for each regimen to be identified.
Indirect costs (e.g. days lost from work) were not
considered in this analysis because of the chosen
perspective (third party payer) and concerns about
the availability and reliability of this type of infor-
mation in the patients’ records.
Results
Identification of treatment regimens
Table 1 shows that fludarabine, CHOP  and CVP
(cyclophosphamide, vincristine, prednisone) were
cited with comparable frequency by specialists in
Canada. CHOP and CVP were cited most in Italy,
and CHOP and CVP in Germany. Of particular inter-
est was the use of fludarabine, which was not
approved for use in NHL at the time of interview.
Regimens were chosen for economic analysis based
on the level of usage in each country: Canada
(CHOP, CVP and fludarabine), Germany (CHOP and
CVP), Italy (CHOP and fludarabine) (Table 2).
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Table 1. Most frequently used protocols for relapsed low-
grade NHL by country (1997).
Country Regimen No. of specialists Mean % of patients per 
specialist
Germany CHOP 14 39
COP / CVP 14 32
Fludarabine 11 44
PmN/MPL/MCP 8 31
KNOSPE 5 39
DEXABEAM 3 30
Italy CHOP 14 36
Fludarabine 13 54
COP / CVP 9 29
Chlorambucil + prednisone 6 26
FND 5 29
CEOP 4 47
Chlorambucil 4 40
Fludarabine + prednisone 3 55
Fludarabine + mitoxantrone 3 8
Canada COP / CVP 22 29
CHOP 20 30
Fludarabine 18 35
Transplantation 6 20
CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone;
COP/CVP: cyclophosphamide, vincristine, prednisone;
PmN: prednimustine, mitoxantrone; MPL: mitoxantrone, prednisone, lomustine;
MCP: mitoxantrone, chlorambucil, prednisone;
KNOSPE: chlorambucil prednisone; DEXABEAM: dexamethasone; 
FND: fludarabine, mitoxantrone, doxorubicin;
CEOP: cyclophosphamide, epirubicin, vincristine, prednisone.
Table 2. Breakdown of patients by treatment regimen and
country.
Canada Germany Italy Total
CHOP 57 48 70 175
CVP 56 51 − 107
Fludarabine 60 − 82 142
Total 173 99 152 424
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Patients
The patients’ characteristics were similar across
treatment regimens and countries. Concomitant
diseases that required treatment occurred in 11-
43% cases across treatment groups (Table 3). Flu-
darabine (Canada) and CVP (Germany) were less
likely to be administered to patients in late-stage
disease (stage 4).
Approximately 48% of returned reports were for
patients undergoing cycles 1–3 of their treatment
course compared to 50% of reports from the lat-
ter half (cycles 4+), with cycles in 6 reports being
unspecified. Neutropenia was the most common
adverse event reported and was evenly spread
across the early and late treatment cycles (Table 4).
The average of the data collected was therefore
assumed to represent those of an average cycle.
Comparative values for adverse events per treat-
ment cycle for relapsed indolent disease were
sought but could not be obtained from published
accounts of randomized trials.
Cost evaluations
Cost components. Unit costs were derived from
a variety of sources (Table 5). Overall treatment
costs were broken down into three components:
cost of regimen medication (drug acquisition), cost
of drug administration, and cost of monitoring and
treating adverse events (Table 6).
Administration costs included both out-patient
visits and hospitalizations for administration of the
drug regimen, plus all routine diagnostic proce-
dures (e.g. blood counts). Overall, administration
costs for each treatment regimen were higher in
the in-patient setting than for out-patient admin-
istration. The difference between the treatment
settings was 14-fold in Italy and Germany, but only
2.5-fold in Canada. The proportion of patients
receiving in-patient treatment also varied between
countries. In Germany, approximately half of all
patients were hospitalized for at least one treat-
ment infusion, whereas in Canada, this was less
than 15% (Table 7).
M. Herold et al.
Table 3. Selected characteristics of the patients.
Canada Italy Germany
CHOP CVP FLU CHOP FLU CHOP CVP
Average age (years) 58 58 62 62 64 58 63
Number of males 35 24 35 43 55 26 34
Number of females 22 32 25 27 27 22 17
Stage of disease (% patients)
I 5 3 5 3 0 6 2
II 12 10 20 14 7 17 12
III 23 13 29 31 38 19 53
IV 60 73 46 51 55 58 33
Presence of concomitant disease
requiring treatment (% patients) 43.1 38 25 10.6 11.1 24.5 37.8
Average number of previous treatments 1.6 1.4 1.5 1.5 1.7 1.4 1.5
Table 4. Breakdown of cycles by number of patients and
adverse events.
N. of patients Occurrence of neutropenia (%)
Cycle 1 72 9.8
Cycle 2 69 14.5
Cycle 3 63 11.1
Cycle 4 55 9.1
Cycle 5 36 11.2
Cycle 6 79 7.6
Cycle >6 44 11.4
Unknown 6 −
Total 424 n/a
Table 5. Summary of unit costs in local currencies.
Canada Germany Italy
Cost Source Cost Source Cost Source
(Can$) (DM) (Lira)
In-patient stay 521 1 650 5 694,900 7
Out-patient visit 189 2 31.8 5 50,000 8
Selected diagnostic tests
Complete blood count 21.71 1 10.8 5 6200 9
U&E 12.72 3 7.2 5 2400 9
Platelets 12.72 3 3.6 5 2400 9
Blood culture 19.04 3 18 5 4000 9
Packed cell transfusion 32.7 3 280 5 50,000 9
Platelet transfusion 37.06 3 107 5 22,500 9
Drug costs − 4 − 6 − 10
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For in-patient therapy, administration costs
formed the major cost component for each regimen
studied (Table 6). The cost of administration repre-
sented 68–73% of total costs for CVP treatment,
51–63% for fludarabine and 44–59% for CHOP
(Figure 1a). In the out-patient setting, the propor-
tion of administration costs was most influenced
by country not regimen. In Canada, this represent-
ed 24–45% of the total, whereas in Italy and Ger-
many, it ranged from 5.5% to 15% (Figure 1b).
Drug acquisition costs were greatest for fludara-
bine and lowest for CVP, irrespective of country of
treatment (Table 6). Drug acquisition formed the
main component of the cost of fludarabine treat-
ment in the out-patient setting (46–58%; Figure
1b), and represented about one-quarter of the total
cost for in-patient administration (Figure 1a). In
contrast, drug acquisition represented less than
10% of the total cost of CVP treatment, and
7–17.5% of the total for CHOP therapy for in-
patient administration and 24–36% in the out-
patient setting (Figure 1).
The monitoring and treatment of adverse events
was the major cost component (52–75%) for both
CHOP and CVP treatment in the out-patient setting
(Figure 1b), whereas for in-patient administration,
the proportion ranged from 24–40%. For fludara-
bine, the proportion of costs due to adverse events
was most affected by country, rather than admin-
istration setting, being 9% (in-patient) and 15%
(out-patient) in Canada, and 27% (in-patient) and
37% (out-patient) in Italy.
Adverse event costs by category
Data were collected on rates of adverse events
for each treatment (Table 8). Given the retrospec-
tive nature of the data, differences in patient selec-
tion criteria, and adverse event reporting and reg-
ulations between countries, interpretation of the
data and cross-country comparisons should be
approached cautiously.
For the majority of regimens, the management of
neutropenia and fever/infection was the greatest
component of adverse event cost (Table 9). The
exception was fludarabine treatment in Italy; costs
for management of nausea and vomiting exceeded
those for neutropenia and fever/infection. The pro-
portion of total adverse event costs associated with
neutropenia and fever/infection was approximate-
ly one-third for fludarabine treatment in Italy, com-
pared with 90% for the same regimen in Canada.
Costs of other adverse events varied: nausea and
vomiting accounted for between €100–400 (less
than 15% of the total adverse event costs), with
the exception of fludarabine treatment in Italy
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Table 6. Breakdown of the average cost of treatment per patient (in €) into administration (Admin), drug acquisition (Acq) and
adverse event (AE) costs for in-patient and out-patient administration for 6 cycles.
Regimen/country In-patient Out-patient
Admin Acq AEs Total Admin Acq AEs Total
CHOP
Canada 5,639 2,217 5,036 12,892 2,187 2,216 5,036 9,439
Germany 5,512 1,706 2,515 9,733 444 1,706 2,515 4,664
Italy 3,781 470 2,179 6,430 335 929 2,179 3,445
CVP
Canada 7,198 162 3,252 10,612 2,847 162 3,252 6,261
Germany 8,088 361 2,658 11,107 506 361 2,658 3,525
Fludarabine
Canada 8,738 3,931 1,273 13,942 3,338 3,931 1,273 8542
Italy 9,166 3,861 4,908 17,940 770 7,723 4,908 1,3401
Conversion rate from local currency to € (April 1998): Canada, 0.672; Germany, 0.511; Italy, 0.000517.
Table 7. Percentage of patients receiving chemotherapy as
in-patients.
Regimen/country Percentage of patients Potential savings per patient 
receiving chemotherapy if overnight stays are avoided
as in-patients
Germany/CHOP 46% 52%
Germany/CVP 51% 68%
Italy/CHOP 19% 40%
Italy/fludarabine 38% 16%
Canada/CHOP 12% 27%
Canada/CVP 14% 41%
Canada/fludarabine 7% 39%
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where it was the most expensive adverse event,
largely due to the extensive use of prophylactic
5HT3 antagonists (almost 40% of total cost) (Table
9). The costs for thrombocytopenia were less than
€100 (CHOP treatment), but showed large varia-
tions for CVP and fludarabine.
Drug regimen costs between countries
No one country consistently demonstrated a sig-
nificantly higher total treatment cost. CHOP ther-
apy (in-patient and out-patient administration)
was most costly in Canada, and least costly in Italy
(Figure 2). Fludarabine treatment cost more in Italy
than in Canada. CVP treatment cost more in Cana-
da than in Germany (out-patient administration),
but the situation was reversed for in-patient
administration.
The greatest difference in costs occurred with
CHOP; treatment in Canada was more than twice
as costly as in Italy (Figure 2). The cost of fludara-
bine treatment in Canada was 79% of that in Italy
(in-patient administration), and approximately
two-thirds of that in the out-patient setting. Sim-
ilar cost variations were seen between Canada and
Germany for CVP therapy.
Total treatment costs within each country
The most marked intra-country difference in
treatment costs occurred in Italy, where fludara-
bine treatment was 3–4 times more expensive than
CHOP, depending on the administration setting
(Figure 2). In Canada, CVP treatment was the least
costly option for both in-patient and out-patient
administration. In Germany, CHOP was more
expensive than CVP (out-patient setting), but
cheaper for in-patient administration. In both
Canada and Germany the difference in treatment
costs was less marked than in Italy.
M. Herold et al.
Table 8. Incidence of grade 3 and 4 adverse events (%
patients).
CHOP Fludarabine CVP
Germany Italy Canada Italy Canada Germany Canada
Neutropenia 8 19 18 18 13 4 9
Fever/infections* 4 11 12 9 8 10 9
Nausea/vomiting 0 0 0 0 2 0 2
Anemia 4 7 7 10 0 12 9
Thrombocytopenia 2 7 2 15 2 2 4
Others 8 11 11 5 5 12 14
None* 17 14 12 29 17 27 11
*Requiring treatment, irrespective of grade.
Figure 1. Costs of drug acquisition, administration and
adverse event management as a proportion of total treat-
ment costs (six cycles) for (a) in-patient and (b) out-patient
administration. (C = Canada; G = Germany; I = Italy; FLU =
fludarabine; conversion rates April 1998.)
Table 9. Average cost per person (€) for the management
of adverse events by category.
CHOP CVP Fludarabine
Canada Germany Italy Canada Germany Canada Italy
Neutropenia 3,873 942 1,625 1,452 1,429 1,149 1655
Nausea/vomiting 142 310 191 138 404 97 1,833
Anemia 42 869 278 61 570 5 595
Thrombocytopenia 95 87 81 776 223 22 659
Other 884 307 4 825 32 0 166
Total 5,036 2,514 2,179 3,252 2,659 1,273 4,908
Conversion rate from local currency to Euros (April 1998): Canada, 0.672;
Germany, 0.511; Italy, 0.000517. 
Discussion
Regimens studied
The telephone survey of lymphoma specialists
confirmed the lack of a standardized treatment
approach to relapsed indolent NHL, both within
and between countries. A similar survey performed
in the UK at the same time39 supports this finding.
The variety of treatment regimens reported by spe-
cialists suggests an overall dissatisfaction with
available options at the time of the study (1997/98)
and highlights the need for more effective treat-
ment strategies.48
In this scenario, treatment-related toxicity
becomes an important consideration. Although the
data for CHOP chemotherapy in indolent NHL are
limited, two recent studies in patients with
untreated aggressive NHL reported an incidence of
grade 4 neutropenia of around 30%.50, 51 Retro-
spective analysis of patients’ records at several
centers in the UK has shown an overall incidence
of neutropenia requiring intervention of 42%.39
Toxicity associated with fludarabine is generally
greater than that associated with CHOP therapy. In
an ECOG study of patients with relapsed indolent
NHL, the incidence of neutropenia was 71%.13 The
incidence of thrombocytopenia can also be high,
with values of 48% reported in both previously
treated and untreated patients.14 Fludarabine treat-
ment is also often associated with problems of
infection (incidences of 15% reported in the ECOG
study), and there are reports of deaths due to infec-
tion in 5-12% of patients.12, 14, 22
Interpretation of the adverse event data needs
care, as there is the possibility of pre-selection bias
in retrospective reviews of patients’ record. Treat-
ment choices would have been based on factors
such as age, disease stage, previous response and
toxicity of previous regimens, which may have
resulted in different adverse event rates to those
expected from prospective, randomized trials.
However, these findings can be considered more
representative of the real life situation and there-
fore suitable for a cost of illness analysis. Adverse
event rates, particularly grade 3 and 4 toxicities
were similar for fludarabine and CHOP and lower
for CVP, suggesting that selection of patients may
compensate for the differences in toxicity profiles
of regimens known from prospective, randomized
trials. Although more aggressive treatment regi-
mens generally achieve remission in a shorter time,
the actual duration of the remission is not
improved compared with that activated by less
aggressive treatments. Theoretically, an improved
remission duration would be economically attrac-
tive due to reduced costs because of a possible
delay and/or a reduction in the number of subse-
quent treatments. More importantly, a longer
remission duration would have a favorable impact
on the denominator of a cost-effectiveness calcu-
lation. However, this is beyond the scope of a cost
of illness study and subject of a cost-effectiveness
or cost-utility analysis which requires comparative
long-term data on both costs and clinical conse-
quences of relevant treatments.
Other adverse events and concomitant diseases
requiring treatment were present in 11–43% of
cases (Table 8) in the different treatment groups,
and contributed up to 25% of costs for adverse
event management, or up to 14% of total costs
(Table 9).
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Figure 2. Average cost (in Euros) of a full course of treat-
ment (six cycles) per patient for (a) in-patient and (b) out-
patient administration. (C = Canada; G = Germany; I = Italy;
FLU = fludarabine; conversion rates April 1998.)
Some bias in cycle selection may also have
occurred as the selection of consecutive cases was
not specified, nor was the selection of early or late
cycles predefined. However, the distribution of the
cycles from the 424 records returned suggests that
this was not a major factor, as there was an even
distribution of patients undergoing early cycles
(cycles 1–3, 48%) and late cycles (cycles 4+, 50%).
Performance status was not recorded, and any
assumptions made on this measure would be diffi-
cult. In theory, participating specialists could have
selected patients with few adverse events and
complications (e.g. to reduce documentation work-
load) which would have resulted in an underesti-
mate of costs for adverse events and complica-
tions. On the other hand, one may speculate that
there could have been a preference to report the
most interesting cases, which would have been
likely to result in an overestimate of costs for
adverse events and complications. However, there
was no indication that either of these effects
played a role or specifically had an impact on data
from one treatment group or country.
Collection of economic data
With the absence of available economic data on
treatment for relapsed indolent NHL (clinical trial
data, meta-analyses, database collections), other
methods of data collection were required for this
analysis. The use of specifically designed CRFs
ensured collection of empirical data reflecting clin-
ical practice, rather than relying on specialists’ per-
ceptions and memory. Data collection from
patients’ records provides a close reflection of the
real-life situation. This is illustrated by the use of
fludarabine off label in some countries to treat
relapsed indolent NHL. A 50% response rate for the
return of completed CRFs provided data on 424
patients. This is the first international economic
study in low-grade NHL, and included either more
patients than, or a similar number as those in oth-
er economic studies in NHL.39, 43, 46, 52
Cost comparisons between countries
Cross-country comparisons were interpreted
with caution. Comparison of treatment costs
between countries revealed no clear trends, with
the exception of out-patient administration costs
which were far higher in Canada than elsewhere,
ranging from 3.8-fold greater for fludarabine to
5.8-fold higher for CHOP therapy in Italy. This
reflects the higher unit costs of an out-patient vis-
it in Canada (€ 127) than in Germany (€ 16) or
Italy (€ 26). In contrast, the costs for each day
spent as an in-patient in a non-intensive care unit
were similar in all three countries (Canada, € 350;
Germany, Euros 332; Italy, €279). The difference in
out-patient administration costs accounted for
most of the difference in costs for CVP treatment
between Canada and Germany, although for flu-
darabine treatment, the higher administration
costs in Canada were outweighed by the higher
acquisition and adverse event costs seen in Italy.
The difference in treatment strategies between
countries found at the time of the study may also
have an impact on treatment costs. In general,
management of patients in Germany and Italy
tends to be more aggressive than that in Canada,
where treatment is more likely to be delayed until
symptoms appear and then initiated using milder
regimens.
Financial considerations could also affect the
patients’ management e.g. in some German hospi-
tals reimbursement of drug costs depends on an
overnight stay. This could account for the high pro-
portion of patients (46–51%) in Germany who
received treatment as in-patients.
Cross-country comparison of adverse event
treatment costs showed costs of treating anemia
were substantially (5–10-fold) lower in Canada
than in Germany and Italy. Costs of managing nau-
sea and vomiting were also lower in Canada than
in Germany and Italy. There was no clear national
trend for other categories of adverse events.
Drivers of treatment costs
For most of the regimens studied, drug acquisi-
tion costs made up less than half of the overall
cost of treatment. The major influence on the total
treatment cost, irrespective of country or regimen
used, was administration setting. In-patient
administration increased the cost of treatment as
much as 3-fold over the equivalent out-patient
regimen. Administration costs comprised the
largest proportion of total costs for each regimen
in the in-patient setting (44–73%), but only
between 6–46% of total costs in the out-patient
setting. Potential savings due to a reduction of
overnight stays in hospital for administration of
chemotherapy are considerable, particularly in Ger-
many and Italy (Table 7). In Canada, the vast major-
ity of NHL therapies are administered on an out-
patient basis.
Treatment and monitoring of adverse events
formed the main cost component of CHOP and CVP
therapy in the out-patient setting, accounting for
between 50–75% of total cost. This was also a sig-
nificant proportion of costs for in-patient admin-
istration (CHOP, 26–39%; CVP, 24–31%). Drug
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acquisition costs were the major component for
treatment cost only for fludarabine administered in
the out-patient setting (46–60%). In contrast, they
accounted for less than 10% of the overall treat-
ment costs for CVP therapy.
Only one other analysis of costs of treating
relapsed indolent NHL has been published.42 This
UK study was also a retrospective analysis of
records of patients treated with CHOP or fludara-
bine in several cancer centers, and compared these
costs with those of patients treated in a phase II
trial of the novel anti-CD20 monoclonal antibody,
rituximab. Although not a direct comparison, the
results were interesting, showing that the overall
costs of rituximab treatment were comparable to
those of CHOP and lower than fludarabine, despite
higher acquisition costs (Figure 3). This disparity
may be due to the good tolerability of the anti-
body treatment, as adverse events costs account-
ed for less than 2% of the total overall cost of rit-
uximab treatment, compared with 70% for CHOP.
Such a saving would more than offset the higher
costs of acquisition. An easy-to-administer and
well-tolerated regimen could produce overall cost
benefits for health authorities as well as for
patients and more attention should be paid to this
in the development of new agents. Focusing on
total costs of treatment rather than on drug acqui-
sition costs alone allows the influence of factors
such as tolerability and ease of administration to
be more seen clearly.
An earlier study by Uyl-de Groot et al.46 examin-
ing costs of CHOP chemotherapy in aggressive NHL
reported an average cost of one course (five cycles)
of out-patient therapy of US$3118 (€ 3057). This
is similar to the cost of CHOP therapy in Italy in this
study (€ 3189 for six cycles), although the drug
acquisition (US$1290 [€ 1265]) and out-patient
administration (US$766 [€ 751]) costs were high-
er in the Dutch study. Tolley et al. also reported
estimated treatment costs for indolent NHL and
aggressive NHL.37 Costs per case for patients not
receiving ABMT ranged from £3700–8800 (€
5913–14,062) depending on the type of NHL and
age of the patient. However, since these estimates
represent the lifetime costs of treatment per
patient, including first-line therapy, comparisons
with results reported here are difficult.
Conclusions
To our knowledge, this is the first time a cross-
nation economic analysis has been performed for
lymphoma treatment practices, and the results pro-
vide the first economic data on treatment patterns
and resource use in relapsed indolent NHL in the
selected countries. Analysis of the overall costs of
providing a single cycle of chemotherapy show that
drug acquisition costs generally account for less
than half of the total costs of treatment. The cost
of adverse event management and, particularly in
the in-patient setting, costs of drug administra-
tion are important cost-drivers. Thus, any formal
economic evaluation of the therapeutic options for
relapsed indolent NHL would need to consider the
costs of administering chemotherapy and manag-
ing adverse events in addition to those of drug
acquisition to obtain an accurate picture of the
costs.
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